CannTrust Holdings announced its involvement in a six-month clinical trial to determine the effectiveness of CBD oil capsules treating ALS or Motor Neuron Disease.
CannTrust Holdings (TSX:TRST) announced its involvement in a six-month clinical trial to determine the effectiveness of cannabidiol (CBD) oil capsules treating Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND).
As quoted in the press release:
CannTrust Holdings, one of Canada’s leading licensed producers of medical cannabis, announced today that it has partnered with Australia’s Gold Coast University Hospital (“Gold Coast”) to conduct a randomized, double-blind, placebo-controlled clinical trial to determine the efficacy of CannTrust cannabidiol (CBD) oil capsules in slowing the disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND). Patient safety and tolerability will also be assessed. The study has received Research Ethics Board approval and Australian Therapeutic Good Administration Acknowledgement for the study drug.
The six-month study will be led by Gold Coast Neurologist, Dr. Arman Sabet, MD. Gold Coast is one of Australia’s leading tertiary referral institutions for ALS management and Dr. Sabet has been involved in many international clinical trials specializing in neuromuscular disorders and stroke.
Dr. Sabet’s research will also analyze the effects of CannTrust CBD oil capsules on study participants’ spasticity, pain, weight loss and quality of life.